%PDF-1.7
%
1 0 obj
<>
endobj
187 0 obj
<>/Font<>>>/Fields 192 0 R>>
endobj
188 0 obj
<>stream
application/pdf
Clauber
(S41 V - M\351dico Nefrologista.cdr)
2012-05-02T17:12:12
PScript5.dll Version 5.2.2
2013-03-09T16:11:54-03:00
2013-03-09T16:11:54-03:00
Gnostice PDFtoolkit V2.02
uuid:702d307d-9e77-494f-9ec7-3d3fb41477c2
uuid:e37c9506-f465-4404-9784-e69808bd07b4
endstream
endobj
3 0 obj
<>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/Type/Page>>
endobj
118 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
137 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
142 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
147 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
152 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
157 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
162 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
167 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
172 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
177 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
224 0 obj
<>stream
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
/GS0 gs
q 1 0 0 1 2448.3601 437.18 cm
0 0 m
59.78 0 l
87.18 0 109.6 -23.797 109.6 -52.887 c
109.6 -65.223 l
109.6 -94.313 87.18 -118.11 59.78 -118.11 c
0 -118.11 l
-27.4 -118.11 -49.82 -94.313 -49.82 -65.223 c
-49.82 -52.887 l
-49.82 -23.797 -27.4 0 0 0 c
h
S
Q
Q
BT
0 0 0 1 k
/GS0 gs
/T1_0 11 Tf
1 0 0 1 292.9969 41.9695 Tm
(11)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2479.1599 6638.48 cm
0 0 m
-0.77 -6162.125 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2597.0701 378.672 cm
0 0 m
2125.72 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 234.453 378.66 cm
0 0 m
2125.717 0 l
S
Q
Q
BT
/T1_0 9 Tf
1 0 0 1 350.1119 36.9572 Tm
(FUNCAB - Funda\347\343o Professor Carlos Augusto Bittencourt)Tj
/T1_1 11 Tf
-38.464 727.922 Td
[(N\343o)-642(\351)-642(recomendada)-643(para)-642(o)-642(p\363s-transplante)-643(em)]TJ
0 -12.288 TD
[(adultos,)-167(a)-167(vacina)-167(para:)]TJ
0 -24.577 TD
[(A\))-478(var\355ola.)]TJ
0 -12.288 TD
[(B\))-478(hepatite)-112(A.)]TJ
T*
[(C\))-423(hepatite)-167(B.)]TJ
T*
[(D\))-423(t\351tano.)]TJ
T*
[(E\))-478(influenza)-168(injet\341vel.)]TJ
/T1_0 11 Tf
5.903 106.466 Td
(Quest\343o 47)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 3142.96 6579.4302 cm
0 0 m
1580.42 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2651.21 6638.48 cm
0 0 m
442.2 0 l
469.45 0 491.75 -22.83 491.75 -50.74 c
491.75 -67.36 l
491.75 -95.27 469.45 -118.1 442.2 -118.1 c
0 -118.1 l
-27.26 -118.1 -49.55 -95.27 -49.55 -67.36 c
-49.55 -50.74 l
-49.55 -22.83 -27.26 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 28.2206 424.8628 Tm
[(Diferentes)-504(glomerulopatias)-505(t\352m)-504(sido)-504(associadas)-505(a)]TJ
T*
[(diversas)-346(neoplasias.)-347(Entre)-346(as)-346(alternativas)-346(abaixo,)-346(\351)]TJ
T*
[(verdadeiro)-168(que:)]TJ
0 -24.577 TD
[(A\))-478(o)-193(c\342ncer)-193(de)-193(mama)-193(\351)-193(a)-193(neoplasia)-194(mais)-193(comumente)]TJ
16.254 -12.288 Td
[(associada)-168(a)-167(glomerulopatia)-168(paraneopl\341sica.)]TJ
-16.254 -12.288 Td
[(B\))-478(h\341)-258(forte)-257(associa\347\343o)-258(entre)-258(a)-257(nefropatia)-258(por)-258(IgA)-202(e)-257(o)]TJ
16.254 -12.288 Td
[(carcinoma)-168(de)-167(c\351lulas)-168(renais.)]TJ
-16.254 -12.288 Td
[(C\))-423(a)-246(glomerulopatia)-248(mais)-246(frequentemente)-247(associada)]TJ
16.254 -12.288 Td
[(a)-167(tumores)-167(s\363lidos)-168(\351)-167(a)-167(doen\347a)-168(por)-167(les\365es)-167(m\355nimas)-167(.)]TJ
-16.254 -12.288 Td
[(D\))-423(a)-683(nefropatia)-683(membranosa)-684(\351)-683(a)-683(\372nica)-683(doen\347a)]TJ
16.254 -12.288 Td
[(g)-7(l)-7(o)-7(m)-7(e)-7(r)-7(u)-7(l)-7(a)-7(r)-840(i)-7(n)-7(q)-7(u)-7(e)-7(s)-7(t)-7(i)-7(o)-7(n)-7(a)-7(v)-7(e)-7(l)-7(m)-7(e)-7(n)-7(t)-7(e)-841(a)-7(s)-7(s)-7(o)-7(c)-7(i)-7(a)-7(d)-7(a)-841(a)]TJ
0 -12.288 TD
(neoplasias.)Tj
-16.254 -12.288 Td
[(E\))-478(a)-860(n)-26(e)-26(f)-26(r)-26(o)-26(p)-26(a)-26(t)-26(i)-26(a)-860(m)-26(e)-26(m)-26(b)-26(r)-26(a)-26(n)-26(o)-26(s)-26(a)-860(e)-26(s)-26(t)-26(\341)-860(f)-26(o)-26(r)-26(t)-26(e)-26(m)-26(e)-26(n)-26(t)-26(e)]TJ
16.254 -12.288 Td
[(associada)-168(ao)-167(Linfoma)-167(de)-167(Hodgkin.)]TJ
/T1_0 11 Tf
-10.351 194.468 Td
(Quest\343o 45)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 781.059 3762.5 cm
0 0 m
1580.421 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 289.309 3821.55 cm
0 0 m
442.199 0 l
469.453 0 491.75 -22.83 491.75 -50.74 c
491.75 -67.36 l
491.75 -95.27 469.453 -118.1 442.199 -118.1 c
0 -118.1 l
-27.258 -118.1 -49.555 -95.27 -49.555 -67.36 c
-49.555 -50.74 l
-49.555 -22.83 -27.258 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 28.1498 191.4049 Tm
[(N)-2(o)]TJ
128.79 0 Td
[(n)-2(e)-2(f)-2(r)-2(o)-2(g)-2(\352)-2(n)-2(i)-2(c)-2(o)-2(,)-835(a)-2(s)-836(o)-2(p)-2(\347)-2(\365)-2(e)-2(s)]TJ
-128.79 -12.288 Td
[(preferenciais)-168(de)-167(tratamento)-167(s\343o:)]TJ
0 -24.577 TD
[(A\))-478(a)-167(furosemida)-168(e)-167(outros)-167(diur\351ticos)-168(de)-167(al\347a.)]TJ
0 -12.288 TD
[(B\))-478(os)-167(an\341logos)-168(do)-167(horm\364nio)-168(antidiur\351tico.)]TJ
T*
[(C\))-423(as)-167(dietas)-167(ricas)-167(em)-167(s\363dio)-167(e)-167(prote\355nas.)]TJ
T*
[(D\))-423(a)-167(clorpropamida)-168(e)-167(o)-167(tegretol.)]TJ
T*
[(E\))-478(os)-220(diur\351ticos)-221(tiaz\355dicos)-220(e)-220(os)-220(anti-inflamat\363rios)-221(n\343o)]TJ
16.254 -12.288 Td
(hormonais.)Tj
/T1_2 11 Tf
7.018 98.306 Td
[(D)-2(i)-2(a)-2(b)-2(e)-2(t)-2(e)-2(s)-835(i)-2(n)-2(s)-2(\355)-2(p)-2(i)-2(d)-2(u)-2(s)]TJ
/T1_0 11 Tf
-17.369 20.448 Td
(Quest\343o 46)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 780.473 1800.47 cm
0 0 m
1580.417 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 288.719 1859.53 cm
0 0 m
442.199 0 l
469.457 0 491.754 -22.83 491.754 -50.74 c
491.754 -67.37 l
491.754 -95.28 469.457 -118.11 442.199 -118.11 c
0 -118.11 l
-27.254 -118.11 -49.551 -95.28 -49.551 -67.37 c
-49.551 -50.74 l
-49.551 -22.83 -27.254 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 28.1498 764.8787 Tm
[(Assinale)-173(o\(s\))-172(medicamento\(s\))-173(antidiab\351tico\(s\))-173(oral\(is\))]TJ
T*
[(pass\355vel\(is\))-337(de)-336(uso)-336(em)-336(pacientes)-337(com)-336(doen\347a)-337(renal)]TJ
T*
[(cr\364nica,)-393(que)-393(apresenta\(m\))-393(evid\352ncia\(s\))-394(de)-393(redu\347\343o)]TJ
T*
[(d)-55(e)-888(d)-55(e)-55(s)-54(f)-54(e)-55(c)-54(h)-55(o)-55(s)-888(m)-54(i)-55(c)-54(r)-54(o)-55(v)-54(a)-55(s)-54(c)-54(u)-55(l)-55(a)-55(r)-54(e)-55(s)-888(e)-888(q)-55(u)-55(e)-888(N)-55(\303)-54(O)]TJ
T*
[(necessita\(m\))-167(ajuste)-167(de)-167(dose)-167(na)-167(insufici\352ncia)-168(renal.)]TJ
0 -24.577 TD
[(A\))-478(As)-167(biguanidas)-168(\(metformina\).)]TJ
0 -12.288 TD
[(B\))-478(A)-112(acarbose.)]TJ
T*
[(C\))-423(As)-167(glitazonas.)]TJ
T*
[(D\))-423(O)-167(exenatide.)]TJ
T*
[(E\))-478(A)-112(sitagliptina.)]TJ
/T1_0 11 Tf
5.903 143.331 Td
(Quest\343o 43)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 780.473 6579.4302 cm
0 0 m
1580.417 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 288.719 6638.48 cm
0 0 m
442.199 0 l
469.457 0 491.754 -22.83 491.754 -50.74 c
491.754 -67.36 l
491.754 -95.27 469.457 -118.1 442.199 -118.1 c
0 -118.1 l
-27.254 -118.1 -49.551 -95.27 -49.551 -67.36 c
-49.551 -50.74 l
-49.551 -22.83 -27.254 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 28.1498 585.3608 Tm
[(N)-59(o)-59(s)-893(p)-59(a)-59(c)-59(i)-59(e)-59(n)-59(t)-59(e)-59(s)-893(c)-59(o)-59(m)-893(n)-59(e)-59(f)-59(r)-59(o)-59(l)-59(i)-59(t)-59(\355)-59(a)-59(s)-59(e)-893(r)-59(e)-59(c)-59(o)-59(r)-59(r)-59(e)-59(n)-59(t)-59(e)-59(,)]TJ
T*
[(e)-14(s)-14(p)-14(e)-14(c)-14(i)-14(a)-14(l)-14(m)-14(e)-14(n)-14(t)-13(e)-847(n)-14(o)-14(s)-847(c)-14(a)-14(s)-14(o)-14(s)-847(d)-14(e)-847(h)-14(i)-14(p)-14(e)-14(r)-14(c)-14(a)-14(l)-14(c)-14(i)-14(\372)-14(r)-14(i)-14(a)-14(,)-847(\351)]TJ
T*
[(recomendada)-168(elevada)-168(ingest\343o)-168(de:)]TJ
0 -24.577 TD
[(A\))-478(c\341lcio.)]TJ
0 -12.288 TD
[(B\))-478(s\363dio.)]TJ
T*
[(C\))-423(prote\355nas.)]TJ
T*
[(D\))-423(refrigerantes.)]TJ
T*
[(E\))-478(\341cido)-167(asc\363rbico.)]TJ
/T1_0 11 Tf
5.903 118.755 Td
(Quest\343o 44)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 780.473 5083.4502 cm
0 0 m
1580.417 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 288.719 5142.5 cm
0 0 m
442.199 0 l
469.457 0 491.754 -22.83 491.754 -50.74 c
491.754 -67.36 l
491.754 -95.27 469.457 -118.11 442.199 -118.11 c
0 -118.11 l
-27.254 -118.11 -49.551 -95.27 -49.551 -67.36 c
-49.551 -50.74 l
-49.551 -22.83 -27.254 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 311.5779 584.8988 Tm
[(S\343o)-336(inibidores)-337(da)-336(calcineurina,)-337(as)-336(seguintes)-337(drogas)]TJ
T*
[(usadas)-167(em)-167(transplantes)-168(renais:)]TJ
0 -24.577 TD
[(A\))-478(micofenolato)-168(de)-167(mofetila)-167(e)-167(azatioprina.)]TJ
0 -12.288 TD
[(B\))-478(alentuzumabe)-168(e)-167(basiliximabe.)]TJ
T*
[(C\))-423(sirolimo)-168(e)-167(everolimo.)]TJ
T*
[(D\))-423(ciclosporina)-168(e)-167(tacrolimo.)]TJ
T*
[(E\))-478(belatacepte)-168(e)-167(rituximabe.)]TJ
/T1_0 11 Tf
5.903 106.466 Td
(Quest\343o 48)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 3142.3701 5079.6001 cm
0 0 m
1580.42 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2650.6201 5138.6602 cm
0 0 m
442.2 0 l
469.45 0 491.75 -22.84 491.75 -50.75 c
491.75 -67.37 l
491.75 -95.28 469.45 -118.12 442.2 -118.12 c
0 -118.12 l
-27.26 -118.12 -49.55 -95.28 -49.55 -67.37 c
-49.55 -50.75 l
-49.55 -22.84 -27.26 0 0 0 c
h
S
Q
Q
BT
/T1_1 11 Tf
1 0 0 1 311.6479 423.6158 Tm
[(E)-58(m)-891(p)-58(a)-58(c)-58(i)-58(e)-58(n)-58(t)-58(e)-891(c)-58(o)-58(m)-891(p)-58(r)-58(o)-58(v)-58(\341)-58(v)-58(e)-58(l)-891(d)-58(i)-58(a)-58(g)-58(n)-58(\363)-58(s)-58(t)-58(i)-58(c)-58(o)-891(d)-58(e)]TJ
T*
[(insufici\352ncia)-353(renal)-352(por)-352(necrose)-352(tubular)-352(aguda,)-352(\351)-352(um)]TJ
T*
[(achado)-168(prov\341vel:)]TJ
0 -24.577 TD
[(A\))-478(a)-167(excre\347\343o)-167(fracionada)-168(de)-167(s\363dio)-167(abaixo)-168(de)-167(1%.)]TJ
0 -12.288 TD
[(B\))-478(a)-167(rela\347\343o)-168(ureia/creatinina)-168(s\351rica)-167(acima)-167(de)-167(80.)]TJ
T*
[(C\))-423(a)-167(osmolaridade)-168(urin\341ria)-168(acima)-167(de)-167(500)-167(mOsm.)]TJ
T*
[(D\))-423(a)-167(presen\347a)-168(de)-167(eosin\363filos)-168(no)-167(sedimento)-168(urin\341rio.)]TJ
T*
[(E\))-478(a)-205(rela\347\343o)-205(creatinina)-206(urin\341ria/creatinina)-206(plasm\341tica)]TJ
16.254 -12.288 Td
[(abaixo)-168(de)-167(20.)]TJ
-16.253 -67.124 Td
[(N)-90(o)-923(d)-90(i)-90(a)-90(g)-90(n)-90(\363)-90(s)-89(t)-89(i)-90(c)-89(o)-923(d)-90(i)-90(f)-89(e)-90(r)-89(e)-90(n)-90(c)-89(i)-90(a)-90(l)-923(e)-90(n)-90(t)-89(r)-89(e)-923(P)-89(\372)-90(r)-89(p)-90(u)-90(r)-89(a)]TJ
T*
[(T)37(rombocitop\352nica)-707(T)37(romb\363tica)-724(\(PTT\))-723(e)-723(S\355ndrome)]TJ
T*
[(Hemol\355tico-Ur\352mica)-218(\(SHU\),)-217(\351)-217(favor\341vel)-217(\340)-217(hip\363tese)-217(de)]TJ
T*
[(PTT)-148(a)-167(presen\347a)-168(de:)]TJ
0 -24.577 TD
[(A\))-478(manifesta\347\365es)-168(neurol\363gicas.)]TJ
0 -12.288 TD
[(B\))-478(trombocitopenia.)]TJ
T*
[(C\))-423(insufici\352ncia)-168(renal)-167(aguda.)]TJ
T*
[(D\))-423(anemia)-168(hemol\355tica)-167(microangiop\341tica.)]TJ
T*
[(E\))-478(esquist\363citos)-168(no)-167(sangue)-168(perif\351rico.)]TJ
/T1_0 11 Tf
5.903 308.761 Td
(Quest\343o 49)Tj
0 -177.719 TD
(Quest\343o 50)Tj
ET
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 3142.96 3735.5701 cm
0 0 m
1580.42 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 3142.96 2254.5801 cm
0 0 m
1580.42 0 l
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2651.21 3794.6299 cm
0 0 m
442.2 0 l
469.45 0 491.75 -22.84 491.75 -50.75 c
491.75 -67.37 l
491.75 -95.28 469.45 -118.11 442.2 -118.11 c
0 -118.11 l
-27.26 -118.11 -49.55 -95.28 -49.55 -67.37 c
-49.55 -50.75 l
-49.55 -22.84 -27.26 0 0 0 c
h
S
Q
Q
q
0.12 0 0 0.12 0 0 cm
0 0 0 1 K
4.167 w 22.926 M
q 1 0 0 1 2651.21 2313.6399 cm
0 0 m
442.2 0 l
469.45 0 491.75 -22.84 491.75 -50.75 c
491.75 -67.37 l
491.75 -95.28 469.45 -118.11 442.2 -118.11 c
0 -118.11 l
-27.26 -118.11 -49.55 -95.28 -49.55 -67.37 c
-49.55 -50.75 l
-49.55 -22.84 -27.26 0 0 0 c
h
S
Q
Q
BT
ET
q
1 0 0 1 228.125 8.7720337 cm
0 g
/GS1 gs
/Fm0 Do
Q
endstream
endobj
226 0 obj
<>/Subtype/Form/Type/XObject>>stream
1 g
1 0 0 1 0 0 cm
229.625 10.272 m
365.5327 10.272 l
365.5327 22.368 l
229.625 22.368 l
229.625 10.272 l
f
endstream
endobj
104 0 obj
<>
endobj
122 0 obj
<>
endobj
131 0 obj
<>
endobj
132 0 obj
<>
endobj
134 0 obj
<>stream
x͖kpTO.80ڊ@D`ȍ$l={&~߳ x[TgΦ']p:_93y/y+ae]-D&jnQ?~n+at-]<-n Iwl;]-F꿽r/?ŰF~lVmva-؋V[b۱
3؝][V`Ǯb?Ea0O5^@Ul[^Xxyg[Ȳ\X⯖`K~nIҪ5Ҫ}zj[I`1tMAB?kzza .٪+,f:9J3*xԏ)P 7,80 ESRTxE>aO
QJh&!ot=] Fv
./06n^}GUX*
Mg )mQXZ:Un!tЈ+qѥo5Z\QeD4e!iKǣQRc^Ԑ8G['Cj+ 6SRDM1CV#2m3+,_$PwZ̍b֗V
\"X@D{fOٵ@30QTnf>dӏd+AOCM)UHnsU8Jiz}tW+pR=;a%u$^h;)2OzFauņގ#@v=AB7;Prp8"X
JdVAi \-3z-]"Y(=cUw^h FG3p.SӅ1
1ts_[A8#C>fMĊ/_a\P&
{5f٣j^l4v00L=^52Rv
N/u,سGӬiVq)zURnX%]X/0+ְ7 (!b(t
&sspDH^(,QCj\/1wl"Tf-}b'nmn6רGw